Compare NTST & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTST | TMDX |
|---|---|---|
| Founded | 2019 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | 2020 | 2019 |
| Metric | NTST | TMDX |
|---|---|---|
| Price | $19.66 | $67.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 9 |
| Target Price | $22.02 | ★ $148.22 |
| AVG Volume (30 Days) | 1.1M | ★ 1.9M |
| Earning Date | 04-20-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.28% | N/A |
| EPS Growth | 150.00 | ★ 382.18 |
| EPS | 0.06 | ★ 0.20 |
| Revenue | $195,006,000.00 | ★ $605,494,000.00 |
| Revenue This Year | $19.03 | $24.25 |
| Revenue Next Year | $16.25 | $18.75 |
| P/E Ratio | ★ $332.67 | $342.25 |
| Revenue Growth | 19.79 | ★ 37.13 |
| 52 Week Low | $16.04 | $60.11 |
| 52 Week High | $21.30 | $156.00 |
| Indicator | NTST | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 37.24 | 34.04 |
| Support Level | $17.67 | $60.11 |
| Resistance Level | $21.13 | $71.14 |
| Average True Range (ATR) | 0.33 | 3.63 |
| MACD | -0.11 | 1.64 |
| Stochastic Oscillator | 0.00 | 66.99 |
Netstreit Corp is an internally managed real estate investment trust. The company acquires, owns, and manages single-tenant, retail commercial real estate subject to long-term net leases with high-credit quality tenants across the United States. It focuses on tenants in industries where a physical location is critical to the generation of sales and profits, with a focus on necessity goods and essential services in the retail sector, including home improvement, auto parts, drug stores and pharmacies, general retail, grocers, convenience stores, discount stores, and quick-service restaurants. Majorily operates in U.S. States and Other counties, and derives maximum of revenue from USA.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.